|
|
Article: Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110.
- Article from:
- PR Newswire
- Article date:
- April 22, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented data at the annual meeting of the American Association for Cancer Research (AACR) in Denver, Colorado, showing that its BiTE(R) antibody MT110 can eliminate cancer stem cells (1). Cancer stem cells are thought to be responsible for resistance of human cancers to chemotherapy and for metastatic relapse. MT110 is in a phase 1 dose-escalating clinical trial in patients with lung or gastrointestinal cancer.
BiTE antibodies such as MT110 represent a novel ...